Cubist Pharmaceuticals Appoints Francis P. Tally, M.D. as Vice President, Research and Development

Dr. Francis P. Tally, a renowned infectious disease expert with 23 years of research experience, has been appointed Vice President, Research and Development at Cubist Pharmaceuticals. Previously, Dr. Tally was Executive Director of Infectious Disease, Molecular Biology and Natural Products Research at Lederle Laboratories. He brings a unique clinical perspective and a deep understanding of scientific components necessary for developing new drugs to combat antibiotic-resistant pathogens. With a strong track record in drug discovery and development, Dr. Tally will lead Cubist's research efforts in developing novel antimicrobials to address the growing threat of antibiotic-resistant pathogens. His expertise will be instrumental in advancing Cubist's mission to establish itself as a leading infectious disease chemotherapy company.

Key Takeaways:

• Dr. Francis P. Tally, M.D. has been appointed Vice President, Research and Development at Cubist Pharmaceuticals, bringing 23 years of infectious disease research experience to the role.
• Dr. Tally was previously Executive Director of Infectious Disease, Molecular Biology and Natural Products Research at Lederle Laboratories, where he led worldwide clinical studies for piperacillin/tazobactam and developed new classes of antibiotics.
• He has published over 150 peer-reviewed scientific publications and has been a Clinical Professor of Medicine at New York Medical College.
• Dr. Tally's research focuses on developing genetic systems to study pathogenesis and antibiotic resistance in Bacteroides fragilis and the clinical study of anaerobic infections.
• He has received significant recognition for his work, including a National Institute of Health's five year Research Carper Development Award in 1980.
• Cubist Pharmaceuticals is headquartered in Cambridge, MA, and has completed a $9 million second round of venture financing, with 50 researchers and administrators employed at its 20,000 square feet laboratories.

Statistics:

• 23 years: Dr. Francis P. Tally's experience in infectious disease research.
• 150+: Number of peer-reviewed scientific publications authored by Dr. Tally.
• 1980: Year Dr. Tally received the National Institute of Health's five year Research Carper Development Award.
• 1986: Year Dr. Tally joined Lederle Laboratories as Executive Director of Infectious Disease, Molecular Biology and Natural Products Research.
• 1992: Year piperacillin/tazobactam was registered for sales in Europe.
• 1993: Year the U.S. Food and Drug Administration approved piperacillin/tazobactam for sales in the United States.
• $9 million: Amount of Cubist Pharmaceuticals' second round of venture financing.
• 50: Number of researchers and administrators employed at Cubist Pharmaceuticals' laboratories.
• 20,000: Square footage of Cubist Pharmaceuticals' laboratories.

Sources:

• PRNewswire, June 5, 1995
• Lederle Laboratories
• American Cyanamid/American Home Products
• National Institute of Health
• New England Medical Center
• Tufts University School of Medicine
• New York Medical College